(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
(PQ6)昼夜节律紊乱诱导肝癌发生中的核受体机制
基本信息
- 批准号:10470137
- 负责人:
- 金额:$ 46.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-18 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAcidsAddressAffectAgonistAndrostanolsAnimal ModelAutomobile DrivingBackBile Acid Biosynthesis PathwayBile AcidsBiological MarkersCAR receptorCTNNB1 geneCancer EtiologyCessation of lifeCholestasisChronicChronotherapyCircadian DysregulationCircadian RhythmsCirrhosisCoupledDetectionDevelopmentDrug TargetingEarly DiagnosisEndocrineEpidemicFailureFatty acid glycerol estersFibrosisGene ExpressionGene MutationGenesGeneticGenomeHawaiiHepaticHepatitis CHepatitis C virusHepatocarcinogenesisHomeostasisHourHumanImpairmentIncidenceIndividualInstitutesIntrahepatic CholestasisJet Lag SyndromeKnock-outLengthLesionLightLinkLiverLiver neoplasmsMalignant NeoplasmsMalignant neoplasm of liverMetabolicMetabolic ControlMetabolic syndromeMolecularMutationNoduleNuclearNuclear ReceptorsObesityObesity EpidemicOncogene DeregulationOncogenicOrganPathologicPathologyPathway interactionsPeripheralPopulationPrevalencePreventionPrevention approachPrevention strategyPrimary carcinoma of the liver cellsResistanceRiskRisk FactorsRoleScheduleSecuritySerumSignal PathwaySignal TransductionTestingTherapeuticTumor PromotersWestern WorldWild Type MouseXenobiotic MetabolismXenobioticsbiomarker signaturecarcinogenesiscircadianclinically relevantgene networkgenetic signaturegenome-wideimprovedliver metabolismmouse modelnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelpredictive testpremalignantpreventrare cancerreceptorresponseshift worktranscriptome sequencingtumor
项目摘要
Project Summary
This application addresses NCI PQ6 on how circadian processes affect tumor development by studying
the role of circadian dysfunction of nuclear receptor pathways in non-alcoholic fatty liver disease (NAFLD)-
induced hepatocellular carcinoma (HCC).
HCC, previously considered a rare cancer in the Western world, has increased 3-fold in incidence since
the 1980s, and is currently the fastest rising cause of cancer-related death in the U.S, due to an increase
in incidence in combination of lack of understanding of its mechanism. The increased HCC risk is coupled
with the prevalence of obesity-related NAFLD, which has recently become the leading risk factor for HCC.
However, no efficient approaches for prevention, early diagnosis, and treatment of NAFLD-induced HCCs
are currently available. The increased risk of NAFLD-related HCC is coupled with population-wide chronic
circadian disruption, a common risk factor of obesity, NAFLD, and cancer in humans. We have recently
established a jet-lagged mouse model following a human nightshift schedule. We found that chronic jet-lag
induces metabolic syndrome, NAFLD, and HCC in wild-type mice following a pathophysiological pathway
strikingly similar to that observed in obese humans, with NAFLD progressing to nonalcoholic
steatohepatitis (NASH) and fibrosis prior to HCC detection. We identified intrahepatic cholestasis as the
key pathophysiological mechanism promoting NAFLD-induced HCC, and demonstrated that circadian
dysregulation of nuclear receptor FXR and CAR pathways is an essential oncogenic mechanism that
drives cholestasis and toxic bile acid signaling to promote the progression from NAFLD to NASH, fibrosis,
and eventually HCC.
In this application, we propose 3 aims. 1) Define the circadian profiles of FXR and CAR controlled hepatic
gene networks and jet-lag induced deregulation signatures of these gene networks. 2) Define the role of
Ctnnb1 and Tp53 and other oncogenic mutations in the progression from jet-lag induced liver premalignant
lesions to HCC and the circadian profiles of gene signatures as well as serum biomarkers associated with
hepatocarcinogenesis. 3) Test the predicted abilities of FXR agonist obeticholic acid (OCA) and CAR
inverse agonist androstanol (ANDR) to prevent jet-lag induced cholestasis and HCC.
These studies will significantly improve our understanding of the role of circadian dysfunction in
spontaneous carcinogenesis in general, and NFALD-induced hepatocarcinogenesis in particular. They will
also illuminate new and exciting avenues to develop novel chronotherapy strategies for prevention and
treatment of NAFLD-induced HCC in humans.
项目摘要
这个应用程序解决了NCI PQ6关于昼夜节律过程如何影响肿瘤发展的研究
核受体昼夜节律失调在非酒精性脂肪性肝病中的作用
诱导性肝细胞癌。
此前在西方世界被认为是一种罕见癌症的肝癌,自那以来发病率增加了3倍
20世纪80年代,目前是美国癌症相关死亡人数上升最快的原因,原因是
发病结合缺乏对其发病机制的认识。增加的肝细胞癌风险与
随着肥胖相关NAFLD的流行,NAFLD最近已成为肝细胞癌的首要危险因素。
然而,没有有效的方法来预防、早期诊断和治疗非酒精性脂肪肝所致的肝细胞癌
目前都是可用的。与非酒精性脂肪肝相关的肝癌风险增加与整个人群的慢性疾病有关
昼夜节律紊乱是人类肥胖、非酒精性脂肪肝和癌症的常见危险因素。我们最近做了
按照人类的夜班时间表建立了一种时差反应的小鼠模型。我们发现慢性时差反应
通过病理生理途径诱导野生型小鼠代谢综合征、非酒精性脂肪肝和肝癌
与在肥胖者身上观察到的惊人相似,NAFLD进展为非酒精性
脂肪性肝炎(NASH)和肝细胞癌检测前的纤维化。我们将肝内胆汁淤积症确定为
促进NAFLD诱导的肝癌的关键病理生理机制,并证明昼夜节律
核受体FXR和CAR通路的失调是一种重要的致癌机制
推动胆汁淤积和毒性胆汁酸信号转导,促进NAFLD向NASH、纤维化、
最后是肝细胞癌。
在本申请中,我们提出了三个目标。1)确定FXR和CAR控制的肝脏的昼夜节律
基因网络和时差导致这些基因网络的去调控特征。2)定义
CTNNB1和TP53等癌基因突变与时差致肝癌前病变进展的关系
肝细胞癌的病变和基因特征的昼夜变化以及与之相关的血清生物标志物
肝癌的发生。3)检验FXR激动剂乙酰胆酸(OCA)和CAR的预测能力
反向激动剂雄烷醇(ANDR)预防时差引起的胆汁淤积和肝细胞癌。
这些研究将显著提高我们对昼夜节律紊乱在
一般是自发致癌,特别是NFALD诱发的肝癌。他们会
还阐明了新的和令人兴奋的途径,以开发新的时间疗法战略,以预防和
非酒精性脂肪肝诱发人肝细胞癌的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LONING None FU其他文献
LONING None FU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LONING None FU', 18)}}的其他基金
Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis
肥胖相关肝癌发生中的交感昼夜节律功能障碍
- 批准号:
10685480 - 财政年份:2019
- 资助金额:
$ 46.75万 - 项目类别:
Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis
肥胖相关肝癌发生中的交感昼夜节律功能障碍
- 批准号:
9910373 - 财政年份:2019
- 资助金额:
$ 46.75万 - 项目类别:
Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis
肥胖相关肝癌发生中的交感昼夜节律功能障碍
- 批准号:
10477995 - 财政年份:2019
- 资助金额:
$ 46.75万 - 项目类别:
Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis
肥胖相关肝癌发生中的交感昼夜节律功能障碍
- 批准号:
10238758 - 财政年份:2019
- 资助金额:
$ 46.75万 - 项目类别:
(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
(PQ6)昼夜节律紊乱诱导肝癌发生中的核受体机制
- 批准号:
10231158 - 财政年份:2018
- 资助金额:
$ 46.75万 - 项目类别:
The Study of the Circadian Rhythm in p53 Signaling
p53 信号转导的昼夜节律研究
- 批准号:
7986752 - 财政年份:2010
- 资助金额:
$ 46.75万 - 项目类别:
The Study of the Circadian Rhythm in p53 Signaling
p53 信号转导的昼夜节律研究
- 批准号:
8704353 - 财政年份:2010
- 资助金额:
$ 46.75万 - 项目类别:
The Study of the Circadian Rhythm in p53 Signaling
p53 信号转导的昼夜节律研究
- 批准号:
8519363 - 财政年份:2010
- 资助金额:
$ 46.75万 - 项目类别:
The Study of the Circadian Rhythm in p53 Signaling
p53 信号转导的昼夜节律研究
- 批准号:
8088132 - 财政年份:2010
- 资助金额:
$ 46.75万 - 项目类别:
The Study of the Circadian Rhythm in p53 Signaling
p53 信号转导的昼夜节律研究
- 批准号:
8753027 - 财政年份:2010
- 资助金额:
$ 46.75万 - 项目类别:
相似国自然基金
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
- 批准号:22007039
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
- 批准号:21372217
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
- 批准号:21172061
- 批准年份:2011
- 资助金额:30.0 万元
- 项目类别:面上项目
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
- 批准号:21176225
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
- 批准号:81072511
- 批准年份:2010
- 资助金额:31.0 万元
- 项目类别:面上项目
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
- 批准号:30660215
- 批准年份:2006
- 资助金额:21.0 万元
- 项目类别:地区科学基金项目
相似海外基金
CAREER: Highly Rapid and Sensitive Nanomechanoelectrical Detection of Nucleic Acids
职业:高度快速、灵敏的核酸纳米机电检测
- 批准号:
2338857 - 财政年份:2024
- 资助金额:
$ 46.75万 - 项目类别:
Continuing Grant
Lipid nanoparticle-mediated Inhalation delivery of anti-viral nucleic acids
脂质纳米颗粒介导的抗病毒核酸的吸入递送
- 批准号:
502577 - 财政年份:2024
- 资助金额:
$ 46.75万 - 项目类别:
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 46.75万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 46.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 46.75万 - 项目类别:
Continuing Grant
Integrated understanding and manipulation of hypoxic cellular functions by artificial nucleic acids with hypoxia-accumulating properties
具有缺氧累积特性的人工核酸对缺氧细胞功能的综合理解和操纵
- 批准号:
23H02086 - 财政年份:2023
- 资助金额:
$ 46.75万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 46.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 46.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 46.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Synthetic analogues based on metabolites of omega-3 fatty acids protect mitochondria in aging hearts
基于 omega-3 脂肪酸代谢物的合成类似物可保护衰老心脏中的线粒体
- 批准号:
477891 - 财政年份:2023
- 资助金额:
$ 46.75万 - 项目类别:
Operating Grants